← Back to Skills Marketplace

Alnylam Pharma

Name: Alnylam Pharma
Author: hanxueyuan

by hanxueyuan · GitHub ↗ · v1.0.0 · MIT-0

cross-platform ✓ Security Clean

Downloads

Stars

Active Installs

Versions

Install in OpenClaw

/install alnylam-pharma

Description

Alnylam Pharma pioneers RNAi therapeutics with three approved siRNA drugs for rare genetic and cardiovascular diseases using GalNAc delivery technology.

README (SKILL.md)

历史时间线

2002 诺贝尔奖得主Phillip Sharp和Thomas Tuschl联合创立
2010 与赛诺菲达成30亿美元合作（后来终止回购权利）
2018 FDA批准Onpattro，全球首款RNAi药物
2019 推出Givlaari治疗急性肝卟啉症
2020 Oxlumo获批治疗原发性高草酸尿症
2022 Amvuttra获批，首个皮下注射siRNA，每3个月给药一次
2023 推出Leqvio（与诺华合作）降低胆固醇

商业模式

RNAi（RNA干扰）平台型公司，用siRNA沉默致病基因。核心策略：先用罕见病证明概念，后扩展到更常见病（如心血管疾病）。Leqvio是与诺华合作的降胆固醇药，潜在患者超数千万。

护城河分析

siRNA递送技术（GalNAc偶联）是其核心竞争力——能将药物精准递送到肝细胞，其他公司难以复制。已上市3款产品+数十个临床管线形成数据壁垒。

关键数据

2023年收入约12亿美元
Leqvio峰值销售预测超30亿美元
全球员工约2,500人
市值约250亿美元

有趣事实

Alnylam的名字来自RNAi的字母重排。两位创始人都获得了2006年诺贝尔医学奖（RNAi发现）。

Usage Guidance

This skill appears safe from a security perspective. Treat its company and financial facts as informational content that may need independent verification, but it does not request access or perform actions.

Capability Analysis

Type: OpenClaw Skill Name: alnylam-pharma Version: 1.0.0 The skill bundle contains purely informational content regarding Alnylam Pharmaceuticals, including its history, business model, and financial data. There are no executable code blocks, network requests, or prompt injection attempts in SKILL.md or _meta.json.

Capability Assessment

✓ Purpose & Capability

The skill content is coherent with its stated purpose: providing background information about Alnylam, RNAi therapeutics, business model, and key data.

✓ Instruction Scope

The artifact contains reference information and read_when triggers only; it does not instruct the agent to override user goals, run tools, contact services, or take actions.

✓ Install Mechanism

There is no install specification and no code files, binaries, packages, scripts, or runtime setup.

✓ Credentials

The skill declares no environment variables, credentials, config paths, OS requirements, network access, or local file access.

✓ Persistence & Privilege

There is no evidence of persistence, background execution, privilege use, memory writes, or ongoing autonomous behavior.

How to Use

Make sure OpenClaw is installed (local or Docker)
Run the install command in chat: /install alnylam-pharma
After installation, invoke the skill by name or use /alnylam-pharma
Provide required inputs per the skill's parameter spec and get structured output

Version History

v1.0.0

- 首发版本，介绍Alnylam Pharmaceuticals的基本情况、发展历史和核心业务。 - 补充了公司在RNAi疗法领域的里程碑事件和多款已上市药物。 - 罗列关键财务数据和商业合作信息，突出技术及数据壁垒。 - 加入行业分析、适用场景和有趣事实，便于快速了解公司。

Metadata

Slug alnylam-pharma

Version 1.0.0

License MIT-0

All-time Installs 0

Active Installs 0

Total Versions 1

Frequently Asked Questions

What is Alnylam Pharma?

Alnylam Pharma pioneers RNAi therapeutics with three approved siRNA drugs for rare genetic and cardiovascular diseases using GalNAc delivery technology. It is an AI Agent Skill for Claude Code / OpenClaw, with 4 downloads so far.

How do I install Alnylam Pharma?

Run "/install alnylam-pharma" in the OpenClaw or Claude Code chat to install it in one step — no extra setup required.

Is Alnylam Pharma free?

Yes, Alnylam Pharma is completely free, licensed under MIT-0. You can download, install and use it at no cost.

Which platforms does Alnylam Pharma support?

Alnylam Pharma is cross-platform and runs anywhere OpenClaw / Claude Code is available (cross-platform).

Who created Alnylam Pharma?

It is built and maintained by hanxueyuan (@hanxueyuan); the current version is v1.0.0.

More Skills